Quantcast

Industry news that matters to you.  Learn more

NanoString Introduces Novel Gene Expression Panel for Immuno-Oncology Research

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced the introduction of a new highly multiplexed gene expression panel for the nCounter® Analysis System, the PanCancer Immune Profiling Panel. This novel panel will enable researchers to create profiles of the human immune response in all cancer types, potentially accelerating the discovery and development of drugs, therapies and predictive biomarker signatures for immunotherapy treatment response.

NanoString Technologies Enters into Biomarker Companion Diagnostic Collaboration with Celgene Corporation to Support Development of REVLIMID as Treatment for Patients with Diffuse Large B-Cell Lymphoma

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced that it has entered into a collaboration with Celgene Corporation to develop a companion diagnostic assay using the nCounter® Analysis System to support the clinical validation of REVLIMID® for treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Under the terms of the collaboration agreement, NanoString will develop, seek regulatory approval for, and commercialize the diagnostic test and is eligible to receive payments totaling up to $45 million of which $5.75 million is an upfront payment, $17 million is for potential success-based developmental and regulatory milestones, and the remainder is for potential commercial payments.

NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna® Breast Cancer Prognostic Gene Signature Assay for assessing a woman’s 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

NanoString Technologies Introduces Novel PanCancer Gene Expression Panel for Multiplexed Pathway Analysis

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced the launch of the nCounter® PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that offers a unique way for translational researchers to investigate cancer biology across all major cancer pathways. The company made the announcement at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

Newly Published Analytical Validation Study Shows Precision and Reproducibility of PAM50-Based Prosigna Breast Cancer Assay in Multiple Clinical Testing Laboratories

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced that a study published online in the journal BMC Cancer demonstrates the analytical validity of the PAM50-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay. Based on highly concordant results across multiple clinical laboratory sites, technicians, and manufacturing lots of Prosigna reagents, the authors concluded that the study provides a strong body of evidence supporting the decentralized use of the Prosigna Assay on the nCounter Dx Analysis System as a prognostic tool for the risk of recurrence (ROR) in selected breast cancer patients.